Cu‐Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Bai Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China. Hauptthemen laut MEDLINE: Copper, Hydroxides, Nitric Oxide Donors, Antioxidants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Open project of Sichuan Provincial Key Laboratory for Human Disease Gene Study, National Natural Science Foundation of China.
Abstract (Originalsprache)
The prevalence of retinal neovascular diseases necessitates novel treatments beyond current therapies like laser surgery or anti‐VEGF treatments, which often carry significant side effects. A novel therapeutic approach is introduced using copper‐containing layered double hydroxides (Cu‐LDH) nanozymes integrated with nitric oxide‐releasing molecules (GSHNO), forming Cu‐LDH@GSHNO aimed at combating oxidative stress within the retinal vascular system. Combination of synthetic chemistry and biological testing, Cu‐LDH@GSHNO are synthesized, characterized, and assessed for curative effect in HUVECs and an oxygen‐induced retinopathy (OIR) mouse model. The results indicate that Cu‐LDH@GSHNO demonstrates SOD‐CAT cascade catalytic ability, accompanied with GSH and nitric oxide‐releasing capabilities, which significantly reduces oxidative cell damage and restores vascular function, presenting a dual‐function strategy that enhances treatment efficacy and safety for retinal vascular diseases. The findings encourage further development and clinical exploration of nanozyme‐based therapies, promising a new horizon in therapeutic approaches for managing retinal diseases driven by oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
- Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 451163, China.
- Academy of Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, 450000, China.
- National Health Commission Cardiovascular Disease Regenerative Medicine Research Key Laboratory, Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central…
- CAS Engineering Laboratory for Nanozyme, Key Laboratory of Biomacromolecules (CAS), CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
ORCID-Profile: Bing Jiang
Förderung
- China Postdoctoral Science Foundation
- Open project of Sichuan Provincial Key Laboratory for Human Disease Gene Study
- National Natural Science Foundation of China
- China Postdoctoral Science Special Foundation
- Institute of Medical Science, the University of Tokyo
Zitieren
APA
Xue, B., Lu, Y., Wang, S., Wu, T., Wang, L., Xiao, Q., Jiang, W., Yan, X., & Jiang, B. (2024). Cu‐Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401600
Vancouver
Xue B, Lu Y, Wang S, Wu T, Wang L, Xiao Q, et al. Cu‐Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401600
BibTeX
@article{Xue2024,
author = {Xue, Bai and Lu, Yu and Wang, Shuyu and Wu, Tingting and Wang, Lulu and Xiao, Qing and Jiang, Wei and Yan, Xiyun and Jiang, Bing},
title = {Cu‐Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401600}
}
EUVIMED